38
|
Basel, Switzerland. September 10, 2025, 7am CEST
|
- BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, extending BV100 IP protection to over 25 countries, including the US, Europe and the UK
- Alpibectir: First patient dosed in a Phase 2 combination trial in pulmonary Tuberculosis by partner GSK – first top line data expected in Q2 2026; EMA Orphan Designation received…